Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia

BMC Research Notes

Table 1 Characteristics of CLL patients

Parameter	Frequency no (%)	Parameter	Frequency no (%)
Age		Hemoglobin (g/dl) ^a
≥ 60	65 (65.7%)	Severe anemia	12 (12.1%)
< 60	34 (34.3%)	Moderate anemia	32 (32.3%)
Sex		Mild anemia	28 (28.3%)
Male	69 (69.7%)	No anemia	27 (27.3%)
Female	30 (30.3%)	Leukocyte count (× 10³/µl)
LN (no of sites involved)		≤ 50	33 (33.3)
Absent	28 (28.3%)	> 50	66 (66.6)
1 site	4 (4.0%)	Modified Rai staging system
2 sites	10 (10.1%)	High risk group	64 (64.7%)
3 sites	2 (2.0%)	Intermediate risk group	30 (30.3%)
> 3 sites	55 (55.6%)	Low risk group	5 (5.0%)
Splenomegaly		Scoring system
Present	52 (52.5%)	Score 3	6 (6.1%)
Absent	47 (47.5%)	Score 3.5	5 (5.1%)
Hepatomegaly		Score 4	31 (31.3%)
Present	25 (25.3%)	Score 4.5	4 (4.0%)
Absent	74 (74.7%)	Score 5	53 (53.5%)
Platelets count (× 10³/µl)		CD 38 positivity
< 150	40 (40.4%)	At 7% cutoff level	68 (68.7%)
150–450	57 (57.6%)	At 20% cutoff level	41 (41.4%)
> 450	2 (2.0)	At 30% cutoff level	36 (36.4%)

Distribution of the most important clinical and laboratory findings. Nearly two-thirds of the participants are within the high-risk group at presentation
^aWHO classification of anemia

ISSN: 1756-0500